AIMS Microbiology, 2019, 5(2): 158-175. doi: 10.3934/microbiol.2019.2.158

Research article

Export file:


  • RIS(for EndNote,Reference Manager,ProCite)
  • BibTex
  • Text


  • Citation Only
  • Citation and Abstract

Antimicrobial activity of bacteriophage derived triple fusion protein against Staphylococcus aureus

1 Floral and Nursery Plants Research Unit, U.S. National Arboretum, Agricultural Research Service, ORISE - U.S. Department of Agriculture, Beltsville, MD, USA
2 Kerry’s Nursery, Miami, FL, USA
3 Animal Biosciences and Biotechnology Laboratory, U.S. Department of Agriculture, Agricultural Research Service, Beltsville, MD, USA
4 Molecular Plant Pathology Laboratory, U.S. Department of Agriculture, Agricultural Research Service, Beltsville, MD, USA

The increasing spread of antibiotic-resistant microorganisms has led to the necessity of developing alternative antimicrobial treatments. The use of peptidoglycan hydrolases is a promising approach to combat bacterial infections. In our study, we constructed a 2 kb-triple-acting fusion gene (TF) encoding the N-terminal amidase-5 domain of streptococcal LambdaSA2 prophage endolysin (D-glutamine-L-lysin endopeptidase), a mid-protein amidase-2 domain derived from the staphylococcal phage 2638A endolysin (N-acetylmuramoyl-L-alanine amidase) and the mature version (246 residues) of the Staphylococcus simulans Lysostaphin bacteriocin (glycyl-glycine endopeptidase) at the C-terminus. The TF gene was expressed in Nicotiana benthamiana plants using the non-replicating Cowpea mosaic virus (CPMV)-based vector pEAQ-HT and the replicating Alternanthera mosaic virus (AltMV)-based pGD5TGB1L8823-MCS-CP3 vector, and in Escherichia coli using pET expression vectors pET26b+ and pET28a+. The resulting poor expression of this fusion protein in plants prompted the construction of a TF gene codon-optimized for expression in tobacco plants, resulting in an improved codon adaptation index (CAI) from 0.79 (TF gene) to 0.93 (TFnt gene). Incorporation of the TFnt gene into the pEAQ-HT vector, followed by transient expression in N. benthamiana, led to accumulation of TFnt to an approximate level of 0.12 mg/g of fresh leaf weight. Antimicrobial activity of purified plant- and bacterial-produced TFnt proteins was assessed against two strains of Gram-positive Staphylococcus aureus 305 and Newman. The results showed that plant-produced TFnt protein was preferentially active against S. aureus 305, showing 14% of growth inhibition, while the bacterial-produced TFnt revealed significant antimicrobial activity against both strains, showing 68 (IC50 25 µg/ml) and 60% (IC50 71 µg/ml) growth inhibition against S. aureus 305 and Newman, respectively. Although the combination of codon optimization and transient expression using the non-replicating pEAQ-HT expression vector facilitated production of the TFnt protein in plants, the most functionally active antimicrobial protein was obtained using the prokaryotic expression system.
  Article Metrics

Keywords endolysins; lysostaphin; antimicrobials; CPMV-based vector; transient expression; codon optimization; Nicotiana benthamiana

Citation: Natalia Y. Kovalskaya, Eleanor E. Herndon, Juli A. Foster-Frey, David M. Donovan, Rosemarie W. Hammond. Antimicrobial activity of bacteriophage derived triple fusion protein against Staphylococcus aureus. AIMS Microbiology, 2019, 5(2): 158-175. doi: 10.3934/microbiol.2019.2.158


  • 1.Tong S, Davis J, Eichenberger E, et al. (2015) Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev 28: 603–661.    
  • 2.Kadariya J, Smith T, Thapaliya D (2014) Staphylococcus aureus and staphylococcal food-borne disease: an ongoing challenge in public health. BioMed Res Int 2014: 1–9.
  • 3.Hennekinne J, Buyder M, Dragacci S (2012) Staphylococcus aureus and its food poisoning toxins: characterization and outbreak investigation. FEMS Microbial Rev 36: 815–836.    
  • 4.Altamirano F, Barr J (2019) Phage therapy in the postantibiotic era. Clin Microbiol Rev 32: e00066–18.
  • 5.Furfaro L, Payne M, Chang B (2018) Bacteriophage therapy: clinical trials and regulatory hurdles. Front Cell Infect Microbiol 8: 1–7.    
  • 6.Lin D, Koskella B, Lin H (2017) Phage therapy: an alternative to antibiotics in the age of multi-drug resistance. World J Gastrointest Pharmacol Ther 8: 162–173.    
  • 7.Liu J, Wang N, Liu Y, et al. (2018) The antimicrobial spectrum of lysozyme broadened by reductive modifications. Poult Sci 97: 3992–3999.    
  • 8.Massschalck B, Michiels C (2003) Antimicrobial properties of lysozyme in relation to foodborne vegetative bacteria. Crit Rev Microbiol 29: 191–214.    
  • 9.Jagielska E, Chojnacka O, Sabała I (2016) LytM fusion with SH3b-like domain expands its activity to physiological conditions. Microb Drug Resist 22: 561–469.
  • 10.Tossavainen H, Raulinaitis V, Kauppinen L, et al. (2018) Structural and functional insights into Lysostaphin-substrate interaction. Front Mol Biosci 5: 1–14.    
  • 11.Channabasappa S, Durgaiah M, Chikkamadaiah R, et al. (2018) Efficacy of novel antistaphylococcal ectolysin P128 in a rat model of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents and Chemother 62: 1–10.
  • 12.Cooper C, Mirzael M, Nilsson A (2016) Adapting drug approval pathways for bacteriophage-based therapeutics. Front Microbiol 7: 1–15.
  • 13.Kashani H, Schmelcher M, Sabzalipoor H, et al. (2018) Recombinant endolysins as potential therapeutics against antibiotic-resistant Staphylococcus aureus: current status of research and novel delivery strategies. Clin Microbiol Rev 31: e00071–17.
  • 14.Love M, Bhandari D, Dobson R, et al. (2018) Potential for bacteriophage endolysins to supplement or replace antibiotics in food production and clinical care. Antibiotics 7: 1–25.
  • 15.Desbois A, Coote P (2011) Bacteriocidal synergy of Lysostaphin in combination with antimicrobial peptides. Eur J Clin Microbiol Infect Dis 30: 1015–1021.    
  • 16.Graham S, Coote P (2007) Potent, synergistic inhibition of Staphylococcus aureus upon exposure to a combination of the endopeptidase Lysostaphin and the cationic peptide ranalexin. J Antimicrob Chemother 59: 759–762.    
  • 17.Hjelm L, Nilvebrant J, Nygren P, et al. (2019) Lysis staphylococcal cells by modular lysin domains linked via a non-covalent barnase-barstar interaction bridge. Front Microbiol 10: 1–9.    
  • 18.Nair S, Desai S, Poonacha N, et al. (2016) Antibiofilm activity and synergistic inhibition of S. aureus biofilms by bactericidal protein P128 in combination with antibiotics. Antimicrob Agents Chemother 60: 7280–7289.
  • 19.Schmelcher M, Donovan D, Loessner M (2012) Bacteriophage endolysins as novel antimicrobials. Future Microbiol 7: 1147–1171.    
  • 20.Roach D, Donovan D (2015) Antimicrobial bacteriophage-derived proteins and therapeutic applications. Bacteriophage 5: e1062590.    
  • 21.Vázquez R, García E, García P (2018) Phage lysins for fighting bacterial respiratory infections: a new generation of antimicrobials. Front Immunol 9: 1–12.    
  • 22.Briers Y, Walmagh M, Grymonprez B, et al. (2014) Art-175 is a highly efficient antibacterial against multidrug-resistant strains and persisters of Pseudomonas aeruginosa. Antimicrob Agents Chemother 58: 3774–3784.    
  • 23.Larpin Y, Oechslin F, Moreillon P. et al. (2018) In vitro characterization of PlyE146, a novel hage lysin that targets Gram-negative bacteria. PLoS ONE 13: e0192507.    
  • 24.Matamp N, Bhat S (2019) Phage endolysins as potential antimicrobials against multidrug resistant Vibrio alginolyticus and Vibrio parahaemolyticus: current status of research and challenges ahead. Microorganisms 7: 1–11.
  • 25.Gerstmans H, Rodríguez-Rubio L, Lavigne R, et al. (2016) From endolysins to Artilysin®s: novel enzyme-based approaches to kill drug-resistant bacteria. Biochem Soc Trans 44: 123–128.    
  • 26.Pastagia M, Euler C, Chahales P, et al. (2011) A novel chimeric lysin shows superiority to mupirocin for skin decolonization of methicillin-resistant and -sensitive staphylococcus aureus strains. Antimicrob Agents Chemother 55, 738–744.
  • 27.Rodríguez-Rubio L, Martínez B, Rodríguez A, et al. (2013) The phage lytic proteins from the Staphylococcus aureus bacteriophage vB_SauS-phiIPLA88 display multiple active catalytic domains and do not trigger staphylococcal resistance. PLoS One 8: e64671.    
  • 28.Becker S, Roach D, Chauhan V, et al. (2016) Triple-acting lytic enzyme treatment of drug-resistant and intracellular Staphylococcus aureus. Sci Rep 6: 1–10.    
  • 29.Donovan D, Foster-Frey J (2008) LambdaSa2 prophage endolysin requires Cpl-7-binding domains and amidase-5domain for antimicrobial lysis of streptococci. FEMS Microbiol Lett 287: 22–33.    
  • 30.Abaev I, Foster-Frey J, Korobova O, et al. (2013) Staphylococcal Phage 2638A endolysin is lytic for Staphylococcus aureus and harbors an inter-lytic-domain secondary translational start site. Appl Microbiol Biotechnol 97: 3449–3456.    
  • 31.Yang X, Li C, Lou R, et al. (2007) In vitro activity of recombinant lysostaphin against Staphylococcus aureus isolates from hospitals in Beijing. China J Med Microbiol 56: 71–76.    
  • 32.Pritchard D, Dong S, Kirk M, et al. (2007) LambdaSa1 and LambdaSa2 prophage lysins of Streptococcus agalactiae. Appl Environ Microbiol 73: 7150–7154.    
  • 33.Lim H-S, Vaira A, Domier L, et al. (2010) Efficiency of VIGS and gene expression in a novel bipartite potexvirus vector delivery system as a function of strength of TGB1 silencing suppression. Virology 402: 149–163.    
  • 34.Peyret H, Lomonossoff G (2013) The pEAQ vector series: the easy and quick way to produce recombinant proteins in plants. Plant Mol Biol 83: 51–58.    
  • 35.Kovalskaya N, Zhao Y, Hammond R (2011) Antibacterial and antifungal activity of a snakin-defensin hybrid protein expressed in tobacco and potato plants. The Open Plant Sci J 5: 29–42.    
  • 36.Kovalskaya N, Hammond RW (2009) Expression and functional characterization of the plant antimicrobial snakin-1 and defensin recombinant proteins. Protein Expr Purif 63: 12–17.    
  • 37.Sainsbury F, Thuenemann E, Lomonossoff G. (2009) pEAQ: versatile expression vectors for easy and quick transient expression of heterologous proteins in plants. Plant Biotechnol J 7: 682–693.    
  • 38.Scholthof H, Scholthof K-B, Jackson A (1996) Plant virus gene vectors for transient expression of foreign proteins in plants. Annu Rev Phytopathol 34: 299–323.    
  • 39.Al-Hawash A, Zhang X, Ma F (2017) Strategies of codon optimization for high-level heterologous protein expression in microbial expression systems. Gene Reports 9: 46–53.    
  • 40.Inouye S, Sahara-Miura Y, Sato J, et al. (2015) Codon optimization of genes for efficient protein expression in mammalian cells by selection of only preferred human codons. Protein Expr Purif 109: 47–54.    
  • 41.Khalili M, Soleyman M, Baazm M, et al. (2015) High-level expression and purification of soluble bioactive recombinant human heparin-binding epidermal growth factor in Escherichia coli. Cell Biol Int 39: 858–864.    
  • 42.Woo J, Liu Y, Mathias A, et al. (2002) Gene optimization is necessary to express a bivalent anti-human anti-T cell immunotoxin in Pichia pastoris. Protein Expr Purif 25: 270–282.
  • 43.Kuta D, Tripathi L (2005) Agrobacterium-induced hypersensitive necrotic reaction in plant cells: a resistance response against Agrobacterium-mediated DNA transfer. Afr J Biotechnol 4: 752–757.
  • 44.Chen Q, Lai H, Hurtado J, et al. (2013) Agroinfiltration as an effective and scalable strategy of gene delivery for production of pharmaceutical proteins. Adv Tech Biol Med 1: 1–21.
  • 45.Kovalskaya N, Foster-Frey J, Donovan D, et al. (2016) Antimicrobial activity of bacteriophages endolysin produced in Nicotiana benthamiana plants. J Microbiol Biotechnol 26: 160–170.    
  • 46.Grӓslund S, Nordlund P, Weigelt J, et al. (2008) Protein production and purification. Nature Methods 5: 135–146.    
  • 47.Vera A, González-Montalbán N, Aris A, et al. (2007) The conformational quality of insoluble recombinant proteins is enhanced at low growth temperatures. Biotechnol Bioeng 96: 1101–1106.    
  • 48.Desai P, Shrivastava N, Padh H (2010) Production of heterologous proteins in plants: strategies for optimal expression. Biotechnolo Adv 28: 427–435.    
  • 49.Dirisala V, Nair R, Srirama K, et al. (2017) Recombinant pharmaceutical protein production in plants: unraveling the therapeutic potential of molecular pharming. Acta Physiol Plant 39: 1–9.    
  • 50.Rosano G, Ceccarelli E (2014) Recombinant protein expression in Escherichia coli: advances and challenges. Front Microbiol 5: 1–17.


Copyright Info: © 2019, Natalia Y. Kovalskaya, licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution Licese (

Download full text in PDF

Export Citation

Copyright © AIMS Press All Rights Reserved